Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689662 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01689662: Completed Phase 2 study, sponsored by Endocyte.
NCT01689662 is a Phase 2 study that has completed, run by Endocyte. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689662, a Phase 2 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The folate receptor (FR) is overexpressed by many different cancer types, including renal cell carcinoma. Besides helping in the diagnosis of cancer, a folate-targeted imaging agent could provide an effective method to identify folate receptor-positive (FR+) cancer patients that may benefit from folate-targeted therapy. Up to 40 subjects, with known or strongly suspected metastatic renal cell carcinoma with at least one target lesion detected by a diagnostic imaging procedure (e.g. ultrasonography, CT, or MRI), will be enrolled in this study.
Interventions
- DRUG Tc 99m EC20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-08 |
| Est. Completion | 2003-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01689662
The ClinicalTrials.gov registry entry for NCT01689662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc 99m EC20 is the first listed.
NCT01689662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01689662 about?
NCT01689662 is a clinical study titled "Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma". The folate receptor (FR) is overexpressed by many different cancer types, including renal cell carcinoma. Besides helping in the diagnosis of cancer, a folate-targeted imaging agent could provide an effective method to identify folate receptor-positive (FR+) cancer patients that may benefit from fol...
What is the current status of trial NCT01689662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-08. Estimated completion is 2003-07.
What interventions are being tested in trial NCT01689662?
The interventions under investigation include: Tc 99m EC20 (DRUG).
Who is sponsoring clinical trial NCT01689662?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.